Filed with the SEC on · Summarized by InvestorsBot
Kevin Sayer, Dexcom’s executive chair and a director, sold 26,756 shares of common stock on July 20 at $76.32 per share, for approximately $2.04 million. He owned 328,970 shares after the sale.
Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.
Subscribe freeDexCom files 8-K (Item 9.01): Exhibit 10.1 — Letter Agreement dated Feb 27, 2026 between DexCom, Inc.
8-K · March 2, 2026
Kevin R.
8-K · March 2, 2026
Dexcom filed Form 8‑K on Feb 26, 2026: Item 9.01 lists Exhibit 99.1 (press release dated Feb 26, 2026) and…
8-K · February 26, 2026
Dexcom ($DXCM) announced on Feb 26, 2026 the appointment of Mr.
8-K · February 26, 2026
Dexcom Board expands to 12; appointed Albert F.
8-K · February 26, 2026
Dexcom filed an 8‑K (Item 9.01) on Feb 12, 2026 — exhibits: Press Release (Ex.
8-K · February 12, 2026